The 3D team has worked on a variety of contracts for a range of clients from investment fund managers to pharma companies and include the following as examples of the work undertaken:
Operational support for the management of a first in human Phase I study
Operational support of asset in Phase II clinical development
Preclinical support of GLP tox-ready project
Due diligence review of pre-clinical package and CMC sections of a potential in-licensing asset
Generation of a report and presentation to potential investors for repurposing of a clinical stage asset with the inclusion of business plan, timelines and budget to clinical milestones.
Project proposal, costing and follow on support for University TTOs.
Provision of mechanism of action rationale, current status and potential future development options to support additional indications of a novel CNS drug candidate.
Literature review of potential new indication of an existing asset with a novel mechanism of action.
Review of literature and proprietary data package for investment fund manager of early stage pre-clinical asset of a potential NewCo.
Whilst at Proximagen, the Directors of 3D Consultants were responsible for managing and leading a workforce of almost 50 scientists and support staff, a budget of ~£15M and programmes spanning from early discovery through to, and including, Phase 2.
During this time, the team worked on multiple discovery and preclinical stage programmes leading to several clinical candidates progressing into the clinic including a VAP-1 Inhibitor which, following a successful outcome in a Phase 2 PoC study, was out-licensed to a top five pharmaceutical company.
As the core management team, the Directors were key contributors to the scientific assessment of business development opportunities, due diligence and external presentations to potential partners both for in-licensing and out-licensing assets.
Previously, part of the team successfully founded Cambridge Biotechnology Ltd with the IP generated and team of scientists recruited subsequently leading to three acquisitions (by Biovitrum, Proximagen and Upsher-Smith).
"3D consultants have provided us with timely high quality consultancy with the exact skills we required and a flexibility reflecting early stage life sciences operations. We would highly recommend."
Biotech company in London area
“We have benefitted from outstanding advice, expertise and a network of seasoned, dynamic professionals with >30 years in their respective fields, whose guidance has saved us months in our program. 3DC expertise has enabled us to devise bespoke clinical, safety and CMC strategies and partners to rapidly advance our lead program through the ups and downs of preclinical development. I can thoroughly recommend 3DC to any biotech that wants to successfully and rapidly progress new portfolio assets to patients and create value.’’
Cambridge-based Biotech company
“3DC provided us with project management and operational support for a first in human Phase I study. The practical experience of 3DC was obvious from the start with an ability to immediately integrate into our team and work effectively with external CROs in a cooperative and productive manner to deliver the study on time and in budget. Our CEO has previously worked with the 3DC team and knows from direct experience that they take a hands-on, pragmatic approach to early drug development, drawing on a wealth of experience to deliver results.”
European Biotech company
"We have the privilege of recommending 3D Consultants based on our long-standing professional interactions with them. 3D consultants are highly experienced scientists with competencies across core drug discovery, preclinical development, and early clinical development disciplines. Without reservation we are happy to recommend 3D consultants for their scientific expertise, decision making prowess, high professional integrity in delivering quality work, and for their responsiveness and commitment to our urgent timelines."
Proximagen LLC (USA)
“Engaging 3DC at the Tau Consortium has provided us with deep pharmaceutical and drug discovery expertise, critical as we take our drug discovery portfolio from Academia to a rigorous drug discovery setting. Their multidisciplinary approach has proven very useful in performing due diligence on a set of projects, where that collective expertise was critical. We are looking to continue to engage 3DC on oversight of integrated drug discovery programs working with external CROs and collaborators. 3DC takes a hands-on, pragmatic approach that draws on a wealth of experience to deliver results.”
Tau Consortium/Rainwater Charitable Foundation (USA)